Ryan Ramagosa, MD
Dermatology · Mobile, ALNPI 1538330238
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $65,156 of the $86,625 with a category attached, or 75.2%. Galderma Laboratories, L.p. accounts for 61.1% of it on its own, with 31 other manufacturers making up the rest. 2025 is the largest year on record at $54,757, more than ten times the $816 reported in 2019. Among dermatology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 397 payments — averaging $218.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$53K
- LEO Pharma Inc.$25K
- Johnson & Johnson$2K
- UCB, Inc.$2K
- AbbVie$1K
- Senseonics, Incorporated$651
- plus $3K from 26 others
What the payments were for
- Consulting fees$12,80815%
- Speaking & faculty fees$65,15675%
- Travel & lodging$1,5092%
- Food & beverage$6,9818%
- Education$1710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 65 | $52,949 |
| LEO Pharma Inc. | 64 | $25,046 |
| Johnson & Johnson | 40 | $2,318 |
| UCB, Inc. | 16 | $1,619 |
| AbbVie | 57 | $1,045 |
| Senseonics, Incorporated | 3 | $651 |
| Sanofi | 24 | $439 |
| Regeneron Healthcare Solutions, Inc. | 18 | $392 |
| Novartis | 17 | $310 |
| Sun Pharmaceutical Industries Inc. | 17 | $286 |
| Lilly USA, LLC | 14 | $253 |
| Organogenesis Inc. | 5 | $245 |
| E.r. Squibb & Sons, L.L.C. | 7 | $136 |
| Amgen | 7 | $135 |
| Pfizer | 7 | $112 |
| Arcutis Biotherapeutics, Inc. | 5 | $98 |
| Incyte Corporation | 5 | $86 |
| Boehringer Ingelheim | 3 | $78 |
| Bristol Myers Squibb | 3 | $75 |
| Janssen Scientific Affairs, LLC | 2 | $67 |
| Aclaris Therapeutics, Inc. | 4 | $60 |
| Almirall LLC | 2 | $37 |
| Dermavant Sciences, Inc. | 2 | $29 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $27 |
| Journey Medical Corporation | 1 | $26 |
| Cipher Pharmaceuticals US LLC | 1 | $22 |
| Mayne Pharma Commercial LLC | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Dermira, Inc. | 1 | $15 |
| VYNE Pharmaceuticals Inc. | 1 | $14 |
| Biofrontera Inc. | 1 | $11 |
| Organon | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$86,625 in reported general payments places this provider in the 90th percentile of 168 dermatology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 14 | $188,151 |
| Dupixent PenDupilumab | 28 | $115,805 |
| AdbryTralokinumab-Ldrm | 16 | $61,684 |
| OpzeluraRuxolitinib Phosphate | 27 | $53,527 |
| Clobetasol Propionate | 148 | $9,267 |
| Fluocinolone Acetonide | 121 | $8,754 |
| Tacrolimus | 43 | $6,660 |
| Fluocinonide | 121 | $6,213 |
| Fluorouracil | 67 | $5,915 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 233 | $4,262 |
| Ammonium Lactate | 159 | $4,215 |
| Tretinoin | 30 | $4,151 |
| Minocycline Hcl | 150 | $3,644 |
| Clindamycin Phosphate | 75 | $3,624 |
| Minoxidil | 173 | $2,681 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| LEO Pharma Inc.Adbry | $25,046 | $61,68416 claims |
| Incyte CorporationOpzelura | $86 | $53,52727 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 168 dermatology providers in Alabama.
Other dermatology in Mobile
- John VanloockMobile$1.4M
- Thomas BenderMobile$142K
- Kathryn DempseyMobile$48K
- Virginia ReederMobile$22K
- Angel AllenMobile$11K
- Dena HowellMobile$8K
- James KrellBirmingham$944K
- Julie HarperBirmingham$920K
- Eric BaumGadsden$896K
- Corey HartmanBirmingham$573K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.